UbiVac

UbiVac is a dynamic biotechnology company dedicated to the research, development, and manufacturing of innovative therapeutic immune activators, vaccines, and cellular immunotherapies in the fight against cancer. With a commitment to pioneering advancements in cancer treatment, UbiVac leverages patented technologies to develop solutions that improve survival rates and outcomes for patients. The company's research has identified a novel class of shared non-mutated cancer neoantigens, paving the way for the development of off-the-shelf Universal Cancer Vaccines.

UbiVac has achieved significant milestones, including the completion of an NCI-funded phase I/II adjuvant trial of its lead agent, DPV-001, which met its endpoints and demonstrated proof-of-concept. This success has led to strategic partnerships with leading institutions such as the Providence Cancer Institute and Incyte, further accelerating the development of groundbreaking immunotherapy treatments. UbiVac is also actively advancing a pipeline of cellular therapies, building on extensive experience in preclinical and clinical studies of adoptive immunotherapy.

UbiVac is headquartered in Portland, US. Committed to innovation and excellence, UbiVac continues to push the boundaries of biotechnology to create effective and accessible cancer immunotherapies. We invite the management team at UbiVac to create a customized and exclusive company showcase and product listing on our platform to further highlight their achievements and drive commercial development.